Prosonix receives Grant Award from the Biomedical Catalyst to accelerate development of multi-component particle
Prosonix has received a grant worth up to £1.3M from the Biomedical Catalyst. The grant will provide matched-funding support for the pre-clinical development of the Company’s Multi-component particle™ (MCP™) platform as a basis for future combination respiratory medicines.
The £180M Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK.
The award will support a research consortium led by Prosonix that includes internationally recognised respiratory disease and drug inhalation experts at three of the UK’s premier academic institutions: Professor Peter Barnes and Dr Omar Usmani at Imperial College, Dr Ben Forbes at King’s College and Professor Rob Price at the University of Bath. The work will focus on applying Prosonix' proprietary particle engineering technology to enable excipient-free, drug-only MCP™ formulations to be developed as inhaled combination medicines for the treatement of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).
The award will also support the development of cutting-edge living tissue-based models of the lung aimed at providing the most accurate information on the delivery, action and effect of inhaled combination therapies in these tissues.
Other news from the department research and development
